[Famciclovir treatment of patients with chronic hepatitis B virus infection]

Related Experiment Video

Updated: Sep 26, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Li Li1, Qing Shao, Jian Zhang

  • 1Department No.4, The 302nd Hospital of PLA, Beijing 100039, China.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi = Zhonghua Shiyan He Linchuang Bingduxue Zazhi = Chinese Journal of Experimental and Clinical Virology
|April 1, 2003
PubMed

Insights

Famciclovir effectively treats chronic hepatitis B virus (HBV) infection, showing significant viral DNA reduction. This nucleoside drug offers a safe and viable treatment option for patients managing chronic HBV.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Chronic hepatitis B virus (HBV) infection poses a significant global health burden.
  • Effective antiviral therapies are crucial for managing chronic HBV and preventing complications.
  • Nucleoside analogs represent a key therapeutic class for HBV treatment.

Purpose of the Study:

  • To evaluate the efficacy and safety of famciclovir in treating chronic hepatitis B virus (HBV) infection.
  • To compare famciclovir's effects against standard treatments like interferon (IFN) alpha and lamivudine.

Main Methods:

  • A randomized controlled trial involving 89 patients with chronic HBV infection.
  • Patients were divided into three groups: famciclovir, IFN alpha, and lamivudine treatment arms.
  • Treatment outcomes were assessed by measuring serum HBV DNA negativity and HBeAg loss.

Main Results:

  • Serum HBV DNA became negative in 40.62% of patients treated with famciclovir, compared to 37.93% with IFN alpha and 67.90% with lamivudine.
  • The rate of serum HBeAg loss was 21.88% for famciclovir, 41.38% for IFN alpha, and 21.43% for lamivudine.
  • The average time to achieve serum HBV DNA negativity was 1.3 months across groups.

Conclusions:

  • Famciclovir demonstrates efficacy in reducing viral load in chronic HBV patients.
  • Famciclovir is a safe nucleoside drug for managing chronic hepatitis B virus infection.
  • Further research may explore famciclovir's long-term benefits and comparative effectiveness.
Abstract

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Concept Videos

Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...